Inari Medical, Inc.
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is desig…
Medical - Devices
US, Irvine [HQ]
Ratios
6 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross Margin | 81.24 | 88.44 | 90.62 | 91.06 | 88.39 | 86.86 | |
| Profit Margin | -148.67 | -3.73 | 9.87 | 3.55 | -7.63 | -0.33 | |
| Operating Margin | -133.84 | 1.57 | 13.19 | 2.41 | -7.33 | -0.74 | |
|
EPS Growth
|
- - | 82.78 | 1,185.86 | -53.49 | -375.00 | 94.76 | |
| EPS USD | -23.00 | -3.96 | 43.00 | 20.00 | -55.00 | -2.88 | |
| Return on Assets (ROA) | -37.74 | -4.28 | 6.44 | 3.16 | -5.81 | -0.24 | |
| Return on Equity (ROE) | 25.74 | 4.87 | 6.89 | 4.11 | -7.02 | -0.35 | |
| Return on Invested Capital (ROIC) | 30.49 | -6.52 | 9.81 | 2.29 | -6.99 | 0.28 | |
| Solvency | |||||||
| Equity Ratio | -100 | - - | - - | - - | - - | - - | |
| Debt/Assets | 36.57 | 43.73 | - - | 9.38 | 6.40 | 4.75 | |
| Debt/Equity | -24.94 | -49.77 | - - | 12.21 | 7.74 | 6.89 | |
| Debt/EBITDA | 134.83 | -320.15 | -626.22 | -578.74 | 148.81 | -100.68 | |
|
Debt/Capitalization
|
-33.22 | -99.07 | - - | 10.88 | 7.19 | 6.45 | |
| Long-Term Debt/Capitalization | -33.22 | -99.07 | - - | 10.61 | 6.91 | 6.13 | |
| Interest Debt per Share USD | 0.24 | 0.42 | 0.04 | 0.59 | 0.62 | 0.57 | |
| Debt Growth | - - | 98.05 | -100.00 | - - | 10.55 | -0.74 | |
| Liquidity | |||||||
| Current Ratio | 1,220.22 | 444.28 | 1,486.29 | 576.76 | 752.85 | 308.57 | |
| Quick Ratio | 1,130.87 | 393.92 | 1,389.06 | 513.85 | 685.39 | 243.89 | |
| Cash Ratio | 1,026.09 | 266.50 | 825.47 | 218.17 | 107.21 | 51.36 | |
| Operating Cash Flow Ratio | -500 | - - | - - | - - | - - | - - | |
| Turnover | |||||||
| Inventory Turnover | 117.16 | 149.51 | 123.68 | 117.59 | 136.60 | 151.21 | |
| Receivables Turnover | 306.30 | 452.40 | 498.68 | 654.02 | 654.27 | 703.99 | |
| Payables Turnover | 179.39 | 231.89 | 430.13 | 378.49 | 581.09 | 613.29 | |
|
Asset Turnover
|
25.39 | 114.78 | 65.24 | 88.91 | 76.06 | 73.21 | |
| Fixed Turnover | 742.31 | 1,534.89 | 1,862.76 | 451.26 | 529.96 | 711.94 | |
| Coverage | |||||||
| Interest Coverage | -1,030.44 | 87.08 | 1,622.82 | 2,261.69 | -9,557.48 | -1,853.06 | |
| Asset Coverage | 200 | 100 | - - | 900 | 1,300 | 1,400 | |
| Cash Flow Coverage (CFGR) | -110.73 | -25.34 | - - | 87.26 | -43.27 | 112.11 | |
| EBITDA Coverage | -1,000 | 100 | 1,600 | 3,700 | -6,300 | 3,600 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | 100 | 100 | 100 | - - | - - | |
| Market Prospects | |||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -0.53 | -0.09 | 0.49 | 0.22 | -0.87 | -0.04 | |
|
Price/Earnings (P/E)
|
-18,821.43 | -107,395.83 | 20,278.72 | 46,206.29 | -11,474.91 | -225,278.18 | |
| Price/Earnings Growth (PEG) | - - | 1,297.32 | -17.10 | -863.86 | 30.60 | 2,377.26 | |
|
Price/Book (P/B)
|
-4,844.50 | -5,232.41 | 1,396.34 | 1,900.72 | 805.36 | 792.75 | |
| Price/Tangible Book (P/TB) | -4,844.50 | -5,232.41 | 1,396.34 | 1,900.72 | 805.36 | 792.75 | |
| Price/Sales (P/S) | 27,982.71 | 4,005.88 | 2,002.03 | 1,641.50 | 875.78 | 746.62 | |
|
Price/Cash Flow (P/CF)
|
-17,544.43 | -41,495.26 | 146,246.48 | 17,839.98 | -24,036.38 | 10,258.44 | |
| Price/Free CF (P/FCF) | -16,409.96 | -25,348.46 | -78,811.52 | 38,397.93 | -14,038.22 | 12,398.41 | |
| Price/Operating CF (P/OCF) | -17,544.43 | -41,495.26 | 146,246.48 | 17,839.98 | -24,036.38 | 10,258.44 |